Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2952-2961

  Travica, Sandra ^a   Pors, Klaus ^b   Loadman, Paul M ^b   Shnyder, Steven D ^b   Johansson, Inger ^a   Alandas, Mohammed N ^b   Sheldrake, Helen M ^b   Mkrtchian, Souren ^a   Patterson, Laurence H ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(5 CHLORO 1H INDOL 2 YL)[1 (CHLOROMETHYL) 1,2 DIHYDROPYRROLO[3,2 E]INDOL 3(6H) YL] METHANONE; [1 (CHLOROMETHYL) 1,2 DIHYDROPYRROLO[3,2 E]INDOL 3 (6H) YL](5 FLURO 1H INDOL 2 YL)METHANONE; [8 (CHLOROMETHYL) 7,8 DIHYDRO 6H FURO[3,2 E]INDOL 6 YL](5 FLURO 1H INDOL 2 YL)METHANONE; CYTOCHROME P450; CYTOCHROME P450 2W1; DOXORUBICIN; DUOCARMYCIN DERIVATIVE; HISTONE H2AX; ICT 2705; ICT 2706; ICT 2726; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR GROWTH;

ANIMALS; BYSTANDER EFFECT; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOTOXINS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDOLES; MICE; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878999256     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0238     Document Type: Article

References (28)

1. Soreide K, Berg M, Skudal BS, Nedreboe BS. Advances in the understanding and treatment of colorectal cancer. Discov Med 2011; 12:393-404.
2. Garajova I, Di Girolamo S, de Rosa F, Corbelli J, Agostini V, Biasco G, et al. Neoadjuvant treatment in rectal cancer: actual status. Chemother Res Pract 2011;2011:839742.
3. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83. (Pubitemid 47321600)
4. Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 2008; 259:1-15. (Pubitemid 350253101)
5. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010;127:1-17.
6. Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 2006;20:176-86. (Pubitemid 43087701)
7. Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Curr Pharm Des 2011; 17:3527-47.
8. Bradshaw TD, Wren JE, Bruce M, Barrett DA, Leong CO, Gaskell M, et al. Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole lysylamide dihydrochloride] in two rodent species. Pharmacology 2009;83:99-109.
9. McFadyen MC, Murray GI. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol 2005;1:259-63.
10. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M. Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 2007;8:1315-25. (Pubitemid 350162848)
11. Karlgren M, Gomez A, Stark K, Svard J, Rodriguez-Antona C, Oliw E, et al. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 2006;341: 451-8. (Pubitemid 43152125)
12. Edler D, Stenstedt K, Ohrling K, Hallstrom M, Karlgren M, Ingelman-Sundberg M, et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study. Eur J Cancer 2009;45:705-12.
13. Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res 2012;32:3869-74.
14. Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, et al. Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. Mol Pharmacol 2010;78:1004-11.
15. Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, Bradshaw TD, et al. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 2011;10:1982-92.
16. Wang K, Guengerich FP. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1. Chem Res Toxicol 2012; 25:1740-51.
17. Wu ZL, Sohl CD, Shimada T, Guengerich FP. Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 2006;69:2007-14. (Pubitemid 43894320)
18. Yoshioka H, Kasai N, Ikushiro S, Shinkyo R, Kamakura M, Ohta M, et al. Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem Biophys Res Commun 2006;345:169-74.
19. Xiao Y, Guengerich FP. Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J Lipid Res 2012;53:1610-7.
20. Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, et al. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun 2011;47:12062-4.
21. Karlgren M, Ingelman-Sundberg M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 2007;11:61-7. (Pubitemid 46099752)
22. Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008;7:14.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68. (Pubitemid 28124064)
24. Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 2010;6:919-38.
25. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 2005;11:1512-20. (Pubitemid 40315234)
26. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995;55:581-9.
27. Doloff JC, Su T, Waxman DJ. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. BMC Cancer 2010;10:487.
28. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett 2012; 324:160-70.